Author/Editor
Tom Gardner and Tim Beyers
Publisher
Motley Fool
Description
Portfolio service pitched as a higher-end “upgrade” from the Motley Fool and in the family of Everlasting Portfolio services, launched with a dozen recommended growth-focused software as a service (SaaS) stocks in 2021 and and aims to maintain that portfolio with updates and additions.
If you’ve subscribed to Motley Fool Everlasting: SaaS Superstars, please click the stars below to indicate your rating for this newsletter, and please share any other feedback about your experience using the comment box below.
Investment Performance
Rating from 1 votes
Rating: 5.0/5. From 1 vote.
Please wait...
Your vote
- 5 Stars 1 Votes
- 4 Stars 0 Votes
- 3 Stars 0 Votes
- 2 Stars 0 Votes
- 1 Stars 0 Votes
Quality Of Writing/Analysis
Rating from 1 votes
Rating: 5.0/5. From 1 vote.
Please wait...
Your vote
- 5 Stars 1 Votes
- 4 Stars 0 Votes
- 3 Stars 0 Votes
- 2 Stars 0 Votes
- 1 Stars 0 Votes
Value For Price
Rating from 1 votes
Rating: 5.0/5. From 1 vote.
Please wait...
Your vote
- 5 Stars 1 Votes
- 4 Stars 0 Votes
- 3 Stars 0 Votes
- 2 Stars 0 Votes
- 1 Stars 0 Votes
Customer Service
Rating from 1 votes
Rating: 5.0/5. From 1 vote.
Please wait...
Your vote
- 5 Stars 1 Votes
- 4 Stars 0 Votes
- 3 Stars 0 Votes
- 2 Stars 0 Votes
- 1 Stars 0 Votes
Do you know the MF stock is pitching to diagnosis heart problems
I’m not sure if this is it but I know Brian Feroldi writes for TMF.
Brian was on The Investors Podcast recently (episode which you can Google and stream) talking about Semler Scientific.
It’s a company that sells an in office monitoring device to detect Peripheral Vascular Disease. From the sound of him talking about it, it seems to just a device performing a simple blood pressure difference between the arms and legs called Ankle Brachial Index. I dismissed the company because an ABI is free to perform in the office with a BP cuff and stethoscope, albeit somewhat cumbersome and time consuming vs a computer report.
He mentioned that it’s both a device and software subscription service because you pay a one time fee for the device but the reports generated from the device are a recurring subscription charge.
Semler trades OTC which isn’t really The Motley Fools usual recommendations.
So I have no idea if that’s what’s being teased at all but it’s at least a possibility.
Semler just recently uplisted to NASDAQ. So, it fits the profile perfectly.